Share this article
Share this article
COLLEGE STATION, Texas, May 12, 2021 /PRNewswire/ Matica Biotechnology, Inc. (Matica Bio) today announced that the Board of Directors has appointed Yun Jeong Song, MD, as the company s new Chief Executive Officer (CEO) to continue its expansion as a CDMO supporting the global cell and gene therapy industry. Dr. Song joined the company effective April 1
st, 2021 after 3 years as CEO of ImmuneOncia Therapeutics, an international joint venture developing immuno-oncology therapies. Dr. Song succeeds Byung Se So, PhD, who will remain with Matica Bio as an advisor.
Matica Biotechnology GMP Facility (College Station TX, USA)
Dr. Song s background spans more than 20 years of basic research, patient care and biopharmaceutical industry leadership. Prior to ImmuneOncia Therapeutics, she held positions at the U.S. National Institutes of Health, Samsung, and Sanofi.
Share this article
Share this article
TEXAS, Feb. 23, 2021 /PRNewswire/ Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located in Providence Park at 2501 Earl Rudder Freeway in College Station.
The groundbreaking ceremony is scheduled for Tuesday, February 23 at 10:00 am. College Station Mayor Karl Mooney attended the event, along with members of the College Station City Council, Bryan Mayor Andrew Nelson, Bryan-College Station Chamber of Commerce President/CEO Glen Brewer, Brazos Valley EDC Board Chair Mike Gentry, and Brazos Valley EDC President/CEO Matt Prochaska.
Share this article
Share this article
COLLEGE STATION, Texas, Dec. 15, 2020 /PRNewswire/ Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a lease agreement for its GMP production facility located in College Station, TX. Construction of the 25,000 ft
2 facility will commence in Q4 2020 and will be dedicated to the production of viral vectors used in cell and gene therapies, vaccines and oncolytic products. When completed, the facility will provide Matica Bio s clients with comprehensive viral vector development, manufacturing and analytical services centrally located in one of the fastest-growing biotech regions in the United States.